Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duomeisu + Carboplatin in Epithelial Ovarian Cancer
NCT03794778Phase 4Unknown
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Mar 2019
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Duomeisu in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
Duomeisu
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03794778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794778.